- Email: [email protected]
Statin editorial most wanted
ARTICLES
inexpensive, fixed-dose artemisinin-based combination antimalarial could make important contributions to “rolling back malaria”.
5
Contributors
6
The study was designed by T T Hien, C Dolecek, N J White, and J J Farrar. Data were gathered by T T Hien, P P Mai, N T Dung, N T Truong, L H Thai, D T H An, T T Thanh, C Dolecek, and J J Farrar. Data were analysed by T T Hien, T T Tan, C Dolecek, K Stepniewska, N J White, and J J Farrar. T T Hien, C Dolecek, K Stepniewska, N J White, and J J Farrar wrote the paper.
7
8
Conflict of interest statement None declared.
Acknowledgments We thank the director and staff of the Hospital for Tropical Diseases, Ho Chi Minh City; the staff of the Dac O Health Station; N Day and N Tuan for statistical advice and comments on this manuscript; and Song Jianping for providing us with information about piperaquine. This study was supported by the Wellcome Trust of Great Britain.
2 3
4
10
11 12
References 1
9
Nosten F, Brasseur P. Combination therapy for Malaria. Drugs 2002; 62: 1315–29. White NJ, Nosten F, Looareesuwan S, et al. Averting a malaria disaster. Lancet 1999; 353: 1965–67. WHO. Antimalarial drug combination therapy: report of a WHO Technical Consultation. Geneva: World Health Organization, April 2001; WHO/CDS/RBM/2001.35. van Vugt MV, Wilairatana P, Gemperli B, et al. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrugresistant Plasmodium falciparum malaria. Am J Trop Med Hyg 1999; 60: 936–42.
13 14
15
Brockman A, Paul REL., Anderson TJC, et al. Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. Am J Trop Med Hyg 1999; 60: 14–21. Newcombe, Robert G. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998; 17: 873–90. Brockman A, Price RN, van Vugt M, et al. Plasmodium falciparum antimalarial drug susceptibility on the northwestern border of Artesunale Thailand during five years of extensive Artesunatemefloquine use. Trans R Soc Trop Med Hyg 2000; 94: 537–44. Huong NM, Hewitt S, Davis TM, et al. Resistance of Plasmodium falciparum to antimalarial drugs in a highly endemic area of southern Viet Nam: a study in vivo and in vitro. Trans R Soc Trop Med Hyg 2001; 95: 325–29. Nosten F, Hien TT, White NJ. Use of artemisinin derivatives for the control of malaria. Med Trop (Mars) 1998; 58 (suppl 3): 45–49. Hien TT. An overview of the clinical use of artemisinin and its derivatives in the treatment of falciparum malaria in Viet Nam. Trans R Soc Trop Med Hyg 1994; 88: S7–8. Raynes K. Bisquinoline antimalarials: their role in malaria chemotherapy. Int J Parasitol 1999; 29: 367–79. Guo XB, Fu LC. Comparative study of artemisinin suppositories and piperaquine phosphate in the treatment of falciparum malaria. Chung Hsi I Chieh Ho Tsa Chih 1989; 9: 475–77. Lin C, Feng-yi Q, Yan-chang Z. Field observations of the antimalarial piperaquine. Chinese Med J 1982; 95: 281–86. Changxiong L, Xiu L, Zaisong H, et al. In vivo sensitivity of Plasmodium falciparum to piperaquine phosphate assayed in Linshui and Baisha Counties, Hainan Province. Chin J Parasitol Parasitic Dis 1989; 7: 163–65. Denis MB, Davis TM, Hewitt S, et al. Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin Infect Dis 2002; 35: 1469–76.
10
most wanted
Statin editorial most wanted October, 2003 1
Statin warmongering (Oct 25, 2003)
7
The Lancet. The statin wars: why AstraZeneca must retreat. DOI:10.1016/S0140-6736(03)14669-7. Lancet 2003; 362: 1341.
2
Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. DOI:10.1016/S0140-6736(03)14567-9. Lancet 2003; 362: 1255–60.
About autism (Oct 4, 2003) Volkmar FR, Pauls D. Autism. DOI:10.1016/S01406736(03)14471-6. Lancet 2003; 362: 1133–41.
3
Use of HRT in a million women (Aug 9, 2003)
8
Beral V and Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. DOI:10.1016/S0140-6736(03)14065-2. Lancet 2003; 362: 419–27.
4
On stroke (Oct 11, 2003) Warlow C, Sudlow C, Dennis M, Wardlaw J, Sandercock P. Stroke. DOI:10.1016/S0140-6736(03)14544-8. Lancet 2003; 362: 1211–24.
5
COPD (Sept 27, 2003) Calverley PMA, Walker P. Chronic obstructive pulmonary disease. DOI:10.1016/S0140-6736(03)14416-9. Lancet 2003; 362: 1053–61.
6
CHARMing (Sept 6, 2003) Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. DOI:10.1016/S01406736(03)14282-1. Lancet 2003; 362: 759–66.
Erythropoietin not for cancer control (Oct 18, 2003)
What’s really the largest threat to women’s health? (Oct 11, 2003) The Lancet. The greatest threat to women’s health. DOI:10.1016/S0140-6736(03)14551-5. Lancet 2003; 362: 1165.
9
E-SIRIUS (Oct 4, 2003) Schofer J, Schlüter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). DOI:10.1016/S0140-6736(03)14462-5. Lancet 2003; 362: 1093–99.
10 Extra CHARMing (Sept 6, 2003) McMurray JJV, Östergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. DOI:10.1016/S01406736(03)14283-3. Lancet 2003; 362: 467–71.
The 10 most wanted Lancet articles downloaded from ScienceDirect (see Lancet 2003; 361: 1265. DOI:10.1016/S01406736(03)12982-0).
22
THE LANCET • Vol 363 • January 3, 2004 • www.thelancet.com
For personal use. Only reproduce with permission from The Lancet publishing Group.
inexpensive, fixed-dose artemisinin-based combination antimalarial could make important contributions to “rolling back malaria”.
5
Contributors
6
The study was designed by T T Hien, C Dolecek, N J White, and J J Farrar. Data were gathered by T T Hien, P P Mai, N T Dung, N T Truong, L H Thai, D T H An, T T Thanh, C Dolecek, and J J Farrar. Data were analysed by T T Hien, T T Tan, C Dolecek, K Stepniewska, N J White, and J J Farrar. T T Hien, C Dolecek, K Stepniewska, N J White, and J J Farrar wrote the paper.
7
8
Conflict of interest statement None declared.
Acknowledgments We thank the director and staff of the Hospital for Tropical Diseases, Ho Chi Minh City; the staff of the Dac O Health Station; N Day and N Tuan for statistical advice and comments on this manuscript; and Song Jianping for providing us with information about piperaquine. This study was supported by the Wellcome Trust of Great Britain.
2 3
4
10
11 12
References 1
9
Nosten F, Brasseur P. Combination therapy for Malaria. Drugs 2002; 62: 1315–29. White NJ, Nosten F, Looareesuwan S, et al. Averting a malaria disaster. Lancet 1999; 353: 1965–67. WHO. Antimalarial drug combination therapy: report of a WHO Technical Consultation. Geneva: World Health Organization, April 2001; WHO/CDS/RBM/2001.35. van Vugt MV, Wilairatana P, Gemperli B, et al. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrugresistant Plasmodium falciparum malaria. Am J Trop Med Hyg 1999; 60: 936–42.
13 14
15
Brockman A, Paul REL., Anderson TJC, et al. Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. Am J Trop Med Hyg 1999; 60: 14–21. Newcombe, Robert G. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998; 17: 873–90. Brockman A, Price RN, van Vugt M, et al. Plasmodium falciparum antimalarial drug susceptibility on the northwestern border of Artesunale Thailand during five years of extensive Artesunatemefloquine use. Trans R Soc Trop Med Hyg 2000; 94: 537–44. Huong NM, Hewitt S, Davis TM, et al. Resistance of Plasmodium falciparum to antimalarial drugs in a highly endemic area of southern Viet Nam: a study in vivo and in vitro. Trans R Soc Trop Med Hyg 2001; 95: 325–29. Nosten F, Hien TT, White NJ. Use of artemisinin derivatives for the control of malaria. Med Trop (Mars) 1998; 58 (suppl 3): 45–49. Hien TT. An overview of the clinical use of artemisinin and its derivatives in the treatment of falciparum malaria in Viet Nam. Trans R Soc Trop Med Hyg 1994; 88: S7–8. Raynes K. Bisquinoline antimalarials: their role in malaria chemotherapy. Int J Parasitol 1999; 29: 367–79. Guo XB, Fu LC. Comparative study of artemisinin suppositories and piperaquine phosphate in the treatment of falciparum malaria. Chung Hsi I Chieh Ho Tsa Chih 1989; 9: 475–77. Lin C, Feng-yi Q, Yan-chang Z. Field observations of the antimalarial piperaquine. Chinese Med J 1982; 95: 281–86. Changxiong L, Xiu L, Zaisong H, et al. In vivo sensitivity of Plasmodium falciparum to piperaquine phosphate assayed in Linshui and Baisha Counties, Hainan Province. Chin J Parasitol Parasitic Dis 1989; 7: 163–65. Denis MB, Davis TM, Hewitt S, et al. Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin Infect Dis 2002; 35: 1469–76.
10
most wanted
Statin editorial most wanted October, 2003 1
Statin warmongering (Oct 25, 2003)
7
The Lancet. The statin wars: why AstraZeneca must retreat. DOI:10.1016/S0140-6736(03)14669-7. Lancet 2003; 362: 1341.
2
Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. DOI:10.1016/S0140-6736(03)14567-9. Lancet 2003; 362: 1255–60.
About autism (Oct 4, 2003) Volkmar FR, Pauls D. Autism. DOI:10.1016/S01406736(03)14471-6. Lancet 2003; 362: 1133–41.
3
Use of HRT in a million women (Aug 9, 2003)
8
Beral V and Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. DOI:10.1016/S0140-6736(03)14065-2. Lancet 2003; 362: 419–27.
4
On stroke (Oct 11, 2003) Warlow C, Sudlow C, Dennis M, Wardlaw J, Sandercock P. Stroke. DOI:10.1016/S0140-6736(03)14544-8. Lancet 2003; 362: 1211–24.
5
COPD (Sept 27, 2003) Calverley PMA, Walker P. Chronic obstructive pulmonary disease. DOI:10.1016/S0140-6736(03)14416-9. Lancet 2003; 362: 1053–61.
6
CHARMing (Sept 6, 2003) Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. DOI:10.1016/S01406736(03)14282-1. Lancet 2003; 362: 759–66.
Erythropoietin not for cancer control (Oct 18, 2003)
What’s really the largest threat to women’s health? (Oct 11, 2003) The Lancet. The greatest threat to women’s health. DOI:10.1016/S0140-6736(03)14551-5. Lancet 2003; 362: 1165.
9
E-SIRIUS (Oct 4, 2003) Schofer J, Schlüter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). DOI:10.1016/S0140-6736(03)14462-5. Lancet 2003; 362: 1093–99.
10 Extra CHARMing (Sept 6, 2003) McMurray JJV, Östergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. DOI:10.1016/S01406736(03)14283-3. Lancet 2003; 362: 467–71.
The 10 most wanted Lancet articles downloaded from ScienceDirect (see Lancet 2003; 361: 1265. DOI:10.1016/S01406736(03)12982-0).
22
THE LANCET • Vol 363 • January 3, 2004 • www.thelancet.com
For personal use. Only reproduce with permission from The Lancet publishing Group.